Humira RA labeling expansion
This article was originally published in Pharmaceutical Approvals Monthly
Abbott's Humira (adalimumab) label was updated to reflect new data that the monoclonal antibody inhibits irreversible joint damage in patients with rheumatoid arthritis for up to five years. A five-year study conducted in patients with long-standing RA demonstrated that roughly 60 percents of patients showed no radiographic progression after five years. Patients with inadequate response to methotrexate received adalimumab plus methotrexate to evaluate radiographic disease progression and safety of the therapy...
You may also be interested in...
In its “robust, holistic hub” online, firms in the VMS product supply chain can determine their needs, “by product, solution or delivery formats,” and use a “comprehensive and unique portfolio” to “turn natural sources into shelf-ready products.”
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.